Italia markets close in 3 hours 58 minutes

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,1900+0,0800 (+1,95%)
Alla chiusura: 04:00PM EDT
4,1900 0,00 (0,00%)
Dopo ore: 04:00PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

    LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat

  • GlobeNewswire

    Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

    LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat

  • GlobeNewswire

    Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

    Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication on the AUTO1/22 Phase 1 study (CARPALL) in Pediatric B-cell Acute Lymphobl